• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NewAmsterdam Pharma Company N.V. (Amendment)

    9/19/23 9:30:57 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email
    SC 13G/A 1 d531152dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    NEWAMSTERDAM PHARMA COMPANY N.V.

    (Name of Issuer)

    Ordinary Shares, nominal value EUR 0.12 per share

    (Title of Class of Securities)

    N62509109

    (CUSIP Number)

    September 11, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. N62509109

     

      1.    

      Names of Reporting Persons

     

      Morningside Venture Investments Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒         (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      British Virgin Islands

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,060,923

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,060,923

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,060,923

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.93% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Based upon 82,324,331 shares of Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2023.

     

    2


    CUSIP No. N62509109

     

      1.    

      Names of Reporting Persons

     

      Frances Anne Elizabeth Richard

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒         (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,060,923

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,060,923

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,060,923

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.93% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Based upon 82,324,331 shares of Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s Form 6-K filed with the SEC on August 7, 2023.

     

    3


    CUSIP No. N62509109

     

      1.    

      Names of Reporting Persons

     

      Jill Marie Franklin

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒         (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,060,923

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,060,923

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,060,923

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.93% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Based upon 82,324,331 shares of Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s Form 6-K filed with the SEC on August 7, 2023.

     

    4


    CUSIP No. N62509109

     

      1.    

      Names of Reporting Persons

     

      Peter Stuart Allenby Edwards

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒         (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,060,923

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,060,923

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,060,923

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.93% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Based upon 82,324,331 shares of Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s Form 6-K filed with the SEC on August 7, 2023.

     

    5


    CUSIP No. N62509109

     

      1.    

      Names of Reporting Persons

     

      Cheung Ka Ho

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒         (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Hong Kong

    Number of

    Shares

      Beneficially  

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,060,923

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,060,923

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,060,923

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.93% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Based upon 82,324,331 shares of Ordinary Shares outstanding as of June 30, 2023, as reported in the Issuer’s Form 6-K filed with the SEC on August 7, 2023.

     

    6


    CUSIP No. N62509109

     

    Item 1.

     

    (a)   

    Name of Issuer

     

    NewAmsterdam Pharma Company N.V.

     

     

     

    (b)   

    Address of Issuer’s Principal Executive Offices

     

    Gooimeer 2-35, 1411 DC Naarden, The Netherlands

     

    Item 2.

     

    (a)   

    Name of Person Filing
    Morningside Venture Investments Limited

    Frances Anne Elizabeth Richard

    Jill Marie Franklin

    Peter Stuart Allenby Edwards

    Cheung Ka Ho

    (b)   

    Address of Principal Business Office or, if none, Residence
    c/o THC Management Services S.A.M.

    2nd Floor, Le Prince De Galles

    3-5 Avenue Des Citronniers

    MC 98000, Monaco

     

    With copies to:

     

    Morningside Technology Advisory, LLC

    Attn: Stephanie O’Brien, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

     

    Springfield Financial Advisory Limited

    Attn: Investment Administration Department

    22nd Floor Hang Lung Centre

    2-20 Paterson Street

    Causeway Bay, Hong Kong

    (c)    Citizenship
    Morningside Venture Investments Limited    British Virgin Islands
    Frances Anne Elizabeth Richard    United Kingdom
    Jill Marie Franklin    United Kingdom
    Peter Stuart Allenby Edwards    United Kingdom
    Cheung Ka Ho    Hong Kong

     

    (d)   

    Title of Class of Securities

     

    Ordinary Shares, nominal value EUR 0.12 per share

    (e)   

    CUSIP Number

     

    N62509109

     

    7


    CUSIP No. N62509109

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)   

    Amount beneficially owned:

     

    Morningside Venture Investments Limited – 4,060,923

    Frances Anne Elizabeth Richard – 4,060,923

    Jill Marie Franklin – 4,060,923

    Peter Stuart Allenby Edwards – 4,060,923

    Cheung Ka Ho – 4,060,923

    (b)   

    Percent of class:

     

    Morningside Venture Investments Limited – 4.93%

    Frances Anne Elizabeth Richard – 4.93%

    Jill Marie Franklin – 4.93%

    Peter Stuart Allenby Edwards – 4.93%

    Cheung Ka Ho – 4.93%

    (c)    Number of shares as to which the person has:
       (i)   

    Sole power to vote or to direct the vote

    Morningside Venture Investments Limited – 0 shares

    Frances Anne Elizabeth Richard – 0 shares

    Jill Marie Franklin – 0 shares

    Peter Stuart Allenby Edwards – 0 shares

    Cheung Ka Ho – 0 shares

     

    8


    CUSIP No. N62509109

     

    (ii)   

    Shared power to vote or to direct the vote

    Morningside Venture Investments Limited – 4,060,923 shares

    Frances Anne Elizabeth Richard – 4,060,923 shares

    Jill Marie Franklin – 4,060,923 shares

    Peter Stuart Allenby Edwards – 4,060,923 shares

    Cheung Ka Ho – 4,060,923 shares

    (iii)   

    Sole power to dispose or to direct the disposition of

    Morningside Venture Investments Limited – 0 shares

    Frances Anne Elizabeth Richard – 0 shares

    Jill Marie Franklin – 0 shares

    Peter Stuart Allenby Edwards – 0 shares

    Cheung Ka Ho – 0 shares

    (iv)   

    Shared power to dispose or to direct the disposition of

    Morningside Venture Investments Limited – 4,060,923 shares

    Frances Anne Elizabeth Richard – 4,060,923 shares

    Jill Marie Franklin – 4,060,923 shares

    Peter Stuart Allenby Edwards – 4,060,923 shares

    Cheung Ka Ho – 4,060,923 shares

     

     

    This statement is filed by: (i) Morningside Venture Investments Limited, a British Virgin Islands exempted company (“MVIL”), with respect to the Ordinary Shares directly and beneficially owned by it; (ii) Frances Anne Elizabeth Richard, with respect to the Ordinary Shares beneficially owned by her as a result of her position as a director with MVIL; (iii) Jill Marie Franklin, with respect to the Ordinary Shares beneficially owned by her as a result of her position as a director with MVIL; (iv) Peter Stuart Allenby Edwards, with respect to the Ordinary Shares beneficially owned by him as a result of his position as a director with MVIL; and (v) Cheung Ka Ho, with respect to the Ordinary Shares beneficially owned by him as a result of his position as a director with MVIL; (Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons”). Frances Anne Elizabeth Richard, Jill Marie Franklin, Peter Stuart Allenby Edwards, and Cheung Ka Ho are the directors of MVIL and share voting and dispositive power with respect to the securities held by MVIL. Ms. Richard, Ms. Franklin, Mr. Edwards and Mr. Cheung each disclaim beneficial ownership of the securities held by MVIL. MVIL is ultimately wholly beneficially owned by a trust over which Adriel Wenbwo Chan and Wong Yuk Lan share authority to remove the trustee.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    The information set forth in Item 2 is incorporated herein by reference.

     

    9


    CUSIP No. N62509109

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    10


     

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

    Dated: September 19, 2023

     

    For and on behalf of:
    MORNINGSIDE VENTURE INVESTMENTS LIMITED
    By:  

    /s/ Frances Anne Elizabeth Richard

      Frances Anne Elizabeth Richard

    /s/ Frances Anne Elizabeth Richard

    Frances Anne Elizabeth Richard

    /s/ Cheung Ka Ho

    Cheung Ka Ho

    /s/ Jill Marie Franklin

    Jill Marie Franklin

    /s/ Peter Stuart Allenby Edwards

    Peter Stuart Allenby Edwards

     

    11

    Get the next $NAMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    10/20/2025$52.00Buy
    H.C. Wainwright
    8/25/2025$45.00Overweight
    Wells Fargo
    7/17/2025$27.00Neutral
    Goldman
    6/17/2025$42.00Buy
    Citigroup
    6/10/2025$44.00Buy
    Stifel
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    12/30/2024$48.00Buy
    H.C. Wainwright
    5/15/2024Buy
    TD Cowen
    More analyst ratings

    $NAMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

    NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoring STAMFORD, Conn. and OXFORD, England, Oct. 14, 2025 /PRNewswire/ -- Caristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, announced its role as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT Cardiovascular Imaging Trial – overseeing all coronary plaque and inflammation measurements and monitoring. The REMBRANDT trial, sponsored by NewAmsterdam Phar

    10/14/25 7:00:00 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

    Frazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. "We appreciate the continued support of our limited partners, many of whom have been with us since the launch of o

    7/31/25 7:00:00 AM ET
    $ARQT
    $MIRM
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Kooij Louise Frederika exercised 72,428 units of Ordinary Shares at a strike of $10.90 and sold $2,335,860 worth of Ordinary Shares (72,428 units at $32.25) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    1/29/26 4:40:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Kooij Louise Frederika sold $2,415,843 worth of Ordinary Shares (72,572 units at $33.29) and exercised 72,572 units of Ordinary Shares at a strike of $10.90 (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    1/27/26 5:38:55 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Somaiya Mayur Ian exercised 100,000 units of Ordinary Shares at a strike of $9.26 and sold $3,260,618 worth of Ordinary Shares (100,000 units at $32.61) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    1/22/26 5:24:59 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on NewAmsterdam Pharma with a new price target

    H.C. Wainwright resumed coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $52.00

    10/20/25 8:45:44 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on NewAmsterdam Pharma with a new price target

    Wells Fargo initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $45.00

    8/25/25 8:22:07 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on NewAmsterdam Pharma with a new price target

    Goldman initiated coverage of NewAmsterdam Pharma with a rating of Neutral and set a new price target of $27.00

    7/17/25 8:08:01 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    SEC Filings

    View All

    SEC Form S-8 filed by NewAmsterdam Pharma Company N.V.

    S-8 - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

    2/18/26 7:07:23 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by NewAmsterdam Pharma Company N.V.

    10-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

    2/18/26 7:00:55 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

    2/18/26 7:00:26 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Topper James N bought $15,639 worth of Ordinary Shares (660 units at $23.70) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/17/25 5:22:34 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $31,487 worth of Ordinary Shares (1,260 units at $24.99) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/10/25 5:19:10 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $11,294 worth of Ordinary Shares (471 units at $23.98) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    8/13/25 4:49:54 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Leadership Updates

    Live Leadership Updates

    View All

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

    5/15/24 4:05:00 PM ET
    $ENGN
    $NAMS
    $NKTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

    New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa

    4/9/24 8:00:00 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care